我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

归芍升白方改善乳腺癌术后化疗骨髓抑制的临床观察*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2021年06期
页码:
28-33
栏目:
临床研究
出版日期:
2022-09-20

文章信息/Info

Title:
Clinical observation of Guishao Shengbai Decoction on Improving Bone Marrow Suppression in Breast Cancer Chemotherapy after Surgery
文章编号:
1000 - 2723(2021)06- 0028 - 06
作者:
马璐王晓培杨鑫肖丽游紫萱刘韬
(成都中医药大学附属医院乳腺外科,四川 成都 610072)
Author(s):
MA Lu WANG Xiaopei YANG Xin XIAO Li YOU Zixuan LIU Tao
(Department of Breast Surgery, Affiliated Hospital of Chengdu Universityof Traditional Chinese Medicine, Chengdu 610072, China)
关键词:
归芍升白方中药乳腺癌术后化疗骨髓抑制
Keywords:
Guishao Shengbai decoction traditional Chinese medicine after breast cancer surgery chemotherapy bone marrow suppression
分类号:
R273
DOI:
10.19288/j.cnki.issn.1000-2723.2021.06.005
文献标识码:
A
摘要:
目的 探究归芍升白方对乳腺癌术后化疗患者骨髓抑制的临床疗效。方法 选取2018年1月-2020年12月我院收治乳腺癌术后化疗患者106例,随机分为对照组和观察组,每组53例,对照组采用CEF化疗方案,观察组在化疗同时给予归芍升白方,观察一个化疗周期(21 d)后临床疗效、中医证候评分、骨髓抑制程度、生活质量评分并评价药物安全性。结果 化疗后,观察组中医证候积分降低(P<0.05),对照组中医证候积分升高(P<0.05),观察组化疗后中医证候积分各项均显著低于对照组(P<0.05);与化疗前比较,2组化疗后各时间点的外周血WBC、Hb、PLT水平均降低(P<0.05),而观察组化疗后各时间点上述指标均显著高于对照组(P<0.05);化疗后,观察组骨髓抑制≥III级发生率为9.43%,显著低于对照组的24.53%(P<0.05);化疗后,2组KPS评分均降低(P<0.05),但化疗后观察组KPS评分高于对照组(P<0.05);化疗期间,观察组恶心呕吐、腹泻和便秘的发生率显著低于对照组(P<0.05),2组肝肾功能异常率差异不具有统计学意义(P>0.05)。结论 归芍升白方可有效抑制乳腺癌术后化疗患者骨髓抑制,安全性较高,值得临床推广。
Abstract:
Objective To explore the clinical efficacy of Guishao Shengbai decoction on bone marrow suppression in patients undergoing chemotherapy after breast cancer surgery. Methods 106 patients undergoing chemotherapy after breast cancer surgery in the hospital were selected between January 2018 and December 2020, and they were randomly divided into control group and observation group with 53 cases in each group. The control group was treated with CEF chemotherapy, and the observation group was given Guishao Shengbai decoction during chemotherapy. The clinical efficacy, scores of TCM syndromes, bone marrow suppression degree and quality of life score were observed after a chemotherapy cycle (21 d), and the drug safety was evaluated. Results After chemotherapy, the scores of TCM syndromes were decreased in observation group (P<0.05) while the scores were increased in control group (P<0.05). After chemotherapy, the scores of various TCM syndromes in observation group were significantly lower than those in control group(P<0.05). Compared with before chemotherapy, the levels of peripheral blood WBC, Hb and PLT were reduced at each time point after chemotherapy in the two groups (P<0.05), and the above indicators in observation group at each time point after chemotherapy were significantly higher than those in control group (P<0.05) After chemotherapy, the incidence rate of bone marrow suppression≥ grade III of 9.43% in observation group was significantly lower than 24.53% in control group(P<0.05). The KPS scores in the two groups were lowered after chemotherapy(P<0.05), but the KPS score was higher in observation group than that in control group after chemotherapy(P<0.05). During chemotherapy, the incidence rates of nausea and vomiting, diarrhea and constipation in observation group were significantly lower than those in control group(P<0.05), and there was no statistically significant difference in abnormal rate of liver-kidney function between the two groups(P>0.05). Conclusion Guishao Shengbai decoction can effectively inhibit the bone marrow suppression in patients undergoing chemotherapy after breast cancer surgery, and it has high safety and is worthy of clinical promotion.

参考文献/References

[1] WU C C,LI M,MENG H B,et al. Analysis of status and countermeasures of cancer incidence and mortality in China[J]. Sci China Life Sci,2019,62(5):640-647.
[2] BARZAMAN K,KARAMI J,ZAREI Z,et al. Breast cancer: Biology, biomarkers, and treatments[J]. Int Immuno-pharmacol,2020,84:106535.
[3] HE M J,WANG N,ZHENG W X,et al. Ameliorative effects of ginsenosides on myelosuppression induced by chemotherapy or radiotherapy[J]. J Ethnopharmacol,2021, 268:113581.
[4] OUN R,MOUSSA Y E,WHEATE N J. The side effects of platinum-based chemotherapy drugs:a review for chemists[J]. Dalton Trans,2018,47(19):6645-6653.
[5] 苗耀东,李英红,沈浩玥,等. 恶性肿瘤化疗所致骨髓抑制的中医药研究进展[J]. 吉林中医药,2019,39(2):273-277.
[6] 王冬,谈谣,于海洋,等. 中药多靶点抗乳腺癌的研究进展[J]. 中南药学,2019,17(10):1600-1607.
[7] 翟文娟,梁 栋,时光喜,等. 自拟调和营卫1号方治疗乳腺癌术后化疗中骨髓抑制及恶心呕吐的临床研究[J]. 中医药导报,2019,25(3):99-102.
[8] 祁永华,孙 晖,张 宁. 中药辅助治疗化疗后骨髓抑制的实验研究进展[J]. 中国医药导报,2020,17(9):21-24.
[[9] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J]. 中国癌症杂志,2017,27(9):695-759.
[10] 商洪才,王保和,张伯礼. 中药新药证候及疗效评价[J]. 中药新药与临床药理,2004,15(5):365-368.
[11] 世界卫生组织. 抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J]. 癌症,1992,4(3):254.
[12] 陈剑,王宙,吕丽媛,等. 芪胶升白胶囊预防结直肠癌术后化疗骨髓抑制临床研究[J]. 北京中医药,2021,40(7):747-750.
[13] 中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019年版)[J]. 中国肿瘤临床,2019,46(17):876-882.
[14] 陈芳芳,王英浩,王玲玲,等. 中医治疗乳腺癌放化疗后骨髓抑制临床进展[J]. 世界中医药,2019,14(8):1974-1978.
[15] 刘 璐,李仁廷,崔旭旭. 李仁廷教授治疗化疗相关性骨髓抑制临床经验[J]. 陕西中医,2020,41(7):954-956.
[16] 刘粉叶,沙其朋,王娓娓. 益气养血法对骨髓抑制小鼠骨髓造血的促增殖作用及机制[J]. 中华中医药学刊,2019,37(10):2328-2331.
[17] 李红涛.中药扶正抗癌方联合化疗对乳腺癌患者肿瘤标志物及免疫功能的影响[J]. 辽宁中医杂志,2020,47(3):131-133.
[18] 祝微,王文娟,周杰,等. 中医药防治肿瘤放化疗后骨髓抑制的用药规律分析[J]. 环球中医药,2020,13(1):40-47.
[19] 丁欢,吴承杰,潘娅岚,等. 黄芪及当归改善化疗后骨髓抑制的分子机制研究进展[J]. 中国医药导报,2020,17(5):23-26.
[20] 曾妙,甘家丽,黄培锋,等. 中医药防治化疗后骨髓抑制疗效及药理机制研究进展[J]. 辽宁中医杂志,2020,47(10):213-216.
[21] 黄红泓,覃日宏,柳贤福. 中药当归的化学成分分析与药理作用探究[J]. 世界最新医学信息文摘,2019,19(58):127.
[22] 徐昊,黄小平,张 伟,等. 黄芪和当归的主要活性成分配伍对骨髓抑制小鼠造血功能的影响[J]. 中国药理学通报,2019,35(5):707-713.
[23] 王成龙,王林元,朱映黎,等. 芍药内酯苷对放射线辐照法致血虚免疫抑制小鼠的补血作用及机制研究[J]. 环球中医药,2017,10(7):782-787.
[24] HUANG Q J,FENG L Z,LI H,et al. Jian-Pi-Bu-Xue-Formula Alleviates Cyclophosphamide-Induced Myelosuppression via Up-Regulating NRF2/HO1/NQO1 Signaling[J]. Front Pharmacol,2020,11:1302.
[25] 贾震宇,李彦品,魏玉芳,等. 扶正益髓方防治乳腺癌术后化疗骨髓抑制的临床研究[J]. 河北中医药学报,2017, 32(1):20-22.
[26] 刘雄伟,周楚瑶,刘静冰,等. 益髓方改善晚期胃癌患者应用卡培他滨所致的骨髓抑制症状的研究[J]. 华南国防医学杂志,2020,34(1):27-31.
[27] 潘志欣,程旭锋,沈秀华,等. 温阳健脾理气汤联合穴位注射防治乳腺癌化疗后胃肠道不良反应临床研究[J]. 中医学报,2016,31(10):1442-1444.
[28] 曹迪,张亚密,全建峰. 中医药改善化疗毒副反应的研究进展[J]. 中国中医急症,2020,29(7):1302-1305.
[29] 刘娟,胡臻,吕茜倩,等. 基于SCI文献分析的中药不良反应科研态势研究[J]. 成都医学院学报,2019,14(4):525-529.

备注/Memo

备注/Memo:
收稿日期: 2021 - 11- 13
* 基金项目: 四川省中医药科学技术研究专项项目(2016Q015)
第一作者简介: 马璐(1994-),女,护师,研究方向:乳腺病的中医药治疗。
更新日期/Last Update: 1900-01-01